The reiteration of a Buy rating by a prominent analyst can instill confidence in current and potential investors, suggesting a positive short-term impact on Pfizer's stock price. The maintained price target of $42 also provides a benchmark for investors, indicating the analyst's belief that the stock has the potential to reach or exceed this value in the near future.